CytomX Therapeutics Files 8-K
Ticker: CTMX · Form: 8-K · Filed: Aug 13, 2025 · CIK: 1501989
| Field | Detail |
|---|---|
| Company | Cytomx Therapeutics, INC. (CTMX) |
| Form Type | 8-K |
| Filed Date | Aug 13, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, regulatory-update
TL;DR
CytomX filed an 8-K on Aug 13, 2025, likely a routine update, no major news.
AI Summary
On August 13, 2025, CytomX Therapeutics, Inc. filed an 8-K report. The filing indicates that the company is providing information under "Other Events" and is not disclosing specific material events that require immediate reporting beyond this general update. The company is incorporated in Delaware and its principal executive offices are located in South San Francisco, California.
Why It Matters
This filing serves as a general update from CytomX Therapeutics, Inc. to the SEC, indicating that the company is adhering to its reporting obligations without detailing any specific material events.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for 'Other Events' and does not disclose any specific material events, suggesting no immediate significant changes or risks are being reported.
Key Numbers
- 001-37587 — SEC File Number (Identifies the company's filing history with the SEC.)
- 27-3521219 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- CytomX Therapeutics, Inc. (company) — Registrant
- August 13, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- South San Francisco, California (location) — Address of Principal Executive Offices
- 650 515-3185 (phone_number) — Registrant's Telephone Number
FAQ
What is the primary purpose of this 8-K filing by CytomX Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report under the 'Other Events' section, indicating a general update to the SEC without specifying any particular material event.
On what date was the earliest event reported in this filing?
The earliest event reported in this filing was on August 13, 2025.
Where are CytomX Therapeutics, Inc.'s principal executive offices located?
CytomX Therapeutics, Inc.'s principal executive offices are located at 151 Oyster Point Blvd, Suite 400, South San Francisco, California, 94080.
What is the company's state of incorporation?
The company's state of incorporation is Delaware.
Does this filing disclose any specific material events or changes?
No, this filing is categorized under 'Other Events' and does not specify any particular material events or changes that require immediate disclosure beyond this general report.
Filing Stats: 885 words · 4 min read · ~3 pages · Grade level 14.9 · Accepted 2025-08-13 08:07:39
Key Financial Figures
- $0.00001 — nge on which registered Common Stock, $0.00001 par value per share CTMX Nasdaq Glo
Filing Documents
- d925542d8k.htm (8-K) — 26KB
- 0001193125-25-179463.txt ( ) — 138KB
- ctmx-20250813.xsd (EX-101.SCH) — 3KB
- ctmx-20250813_lab.xml (EX-101.LAB) — 18KB
- ctmx-20250813_pre.xml (EX-101.PRE) — 11KB
- d925542d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements This report includes forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that are difficult to predict, may be beyond the Company's control, and may cause the actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied in such statements. Accordingly, you should not rely on any of these forward-looking statements, including those relating to the ongoing clinical trial of CX-2051 and the timing of data availability for the Company's clinical trial of CX-2051. Risks and uncertainties that contribute to the uncertain nature of the forward-looking statements include: the unproven nature of the Company's novel PROBODY therapeutic technology; uncertainties around the Company's ability to raise sufficient funds to carry out its planned research and development; Company's clinical trial product candidates are in the initial stages of clinical development and its other product candidates are currently in preclinical development, and the process by which preclinical and clinical development could potentially lead to an approved product is long and subject to significant risks and uncertainties, including the possibility that the results of preclinical research and early clinical trials, including initial CX-2051 results, may not be predictive of future results; the possibility that the Company's clinical trials will not be successful; the possibility that current preclinical research may not result in additional product candidates; the Company's dependence on the success of CX-2051; the Company's reliance on third parties for the manufacture of the Company's product candidates; possible regulatory developments in the United States and foreign countries, including China and the European Union; and the risk that the Company may incur higher costs than expected for research and develo
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. CYTOMX THERAPEUTICS, INC. Date: August 13, 2025 By: /s/ Christopher W. Ogden Christopher W. Ogden SVP, Chief Financial Officer